None listed
Conditions
Interventions
Intervention1: CurQfen: 500mg capsules 2 times in a Day
Control Intervention1: Normal Cucumin: 500mg Capsules 2 times in a Day
Control Intervention2: Placebo: 500mg capsules 2 times in a day with no a
Sponsors
Akay Flavours and Aromatics Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age 35-65 Years ( Both Inclusive) 2) Male and Female Subjects 3) Subjects in general good health. 4) Subjects with a MMSE score between 25 â?? 30
Exclusion criteria
Exclusion criteria: EXCLUSION CRITERIA 1) Subjects with a education qualification less than higher secondary level 2) Subjects who are not familiar with computer/internet use. 3) Subject with dementia/related memory loss illness 4) Subjects diagnosed with learning difficulty such as dyslexia or dyspraxia 5) Suffering from any form of clinically diagnosed disease, including: o Major mental illness (current or previous episode with hospitalization) o Chronic fatigue syndrome o Liver disease o Diabetes mellitus o Heart disease or myocardial infarction o underwent brain surgery o who have a central nervous system illness o neurological lesion 6) Subjects with a known allergy to herbal products 7) Subjects with abnormal biochemical or haematological values 8) Subjects with abnormal blood pressure 9) Pregnant or Lactating Women 10) Any condition that in Opinion of the Investigator, does not justify the Subjectsâ?? participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Comparative changes EEG in basline and after administration of CurQfen -Comparative changes in cognitive assessment test scores Timepoint: Day 0, Day 15, Day 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change in Brain Derived Neurotrophic factor (BDNF) - safety of CurQfenTimepoint: Day 0, Day 30 | — |
Countries
India
Contacts
Public ContactJestin V thomas
Akay Flavours and Aromatics Private Limited
Outcome results
None listed